Back to Stakeholders
Independent Academic Research Groups

NeuroRx, Inc.

United States
3 Trials

NRx Pharmaceuticals (formerly NeuroRx, Nasdaq: NRXP) is a clinical-stage biopharmaceutical company developing a sequential therapy for suicidal bipolar depression: NRX-100 (preservative-free IV ketamine) for acute stabilization followed by NRX-101 (D-cycloserine/lurasidone) for maintenance, both holding FDA Breakthrough Therapy Designation. The company filed an NDA with the FDA for NRX-100 in 2024 in support of accelerated approval.

Quick Facts

Type
Public Biotech
HQ
United States
Website
Visit

Sponsored Trials

3
Unknown statusIII

NRX-101 for Maintenance of Remission From Severe Bipolar Depression in Patients With Suicidal Ideation

Start Date
Compounds
Placebo
Unknown statusIII

NRX100 vs. Placebo for Rapid Stabilization of Acute Suicidal Ideation and Behavior in Bipolar Depression

Start Date
Compounds
Ketamine, Placebo
CompletedII

Sequential Therapy for the Treatment of Severe Bipolar Depression

Start Date
Compounds
Ketamine, Placebo